WO2003043569A3 - Trans-10, cis-12 conjugated linoleic acid isomer for the treatment of diseases - Google Patents
Trans-10, cis-12 conjugated linoleic acid isomer for the treatment of diseases Download PDFInfo
- Publication number
- WO2003043569A3 WO2003043569A3 PCT/US2002/036684 US0236684W WO03043569A3 WO 2003043569 A3 WO2003043569 A3 WO 2003043569A3 US 0236684 W US0236684 W US 0236684W WO 03043569 A3 WO03043569 A3 WO 03043569A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cis
- linoleic acid
- conjugated linoleic
- acid isomer
- trans
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/24—Heavy metals; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/28—Compounds containing heavy metals
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Inorganic Chemistry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2002357729A AU2002357729A1 (en) | 2001-11-16 | 2002-11-12 | Trans-10, cis-12 conjugated linoleic acid isomer for the treatment of diseases |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US33249601P | 2001-11-16 | 2001-11-16 | |
US60/332,496 | 2001-11-16 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2003043569A2 WO2003043569A2 (en) | 2003-05-30 |
WO2003043569A3 true WO2003043569A3 (en) | 2003-10-30 |
Family
ID=23298480
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2002/036684 WO2003043569A2 (en) | 2001-11-16 | 2002-11-12 | Trans-10, cis-12 conjugated linoleic acid isomer for the treatment of diseases |
Country Status (2)
Country | Link |
---|---|
AU (1) | AU2002357729A1 (en) |
WO (1) | WO2003043569A2 (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8933022B2 (en) | 2011-03-01 | 2015-01-13 | Jds Therapeutics, Llc | Methods and compositions for the treatment and prevention Hypoglycemia and related disorders |
US9005637B2 (en) | 2007-06-26 | 2015-04-14 | Jds Therapeutics, Llc | Multiple unit dosage form having a therapeutic agent in combination with a nutritional supplement |
US9119835B2 (en) | 2007-03-13 | 2015-09-01 | JDS Therapeautics, LLC | Methods and compositions for the sustained release of chromium |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SI2396081T1 (en) | 2009-02-16 | 2017-09-29 | Nogra Pharma Limited | Alkylamido compounds and uses thereof |
JP6301844B2 (en) | 2012-02-09 | 2018-03-28 | ノグラ ファーマ リミテッド | How to treat fibrosis |
MX2018009748A (en) | 2016-02-11 | 2019-02-07 | Nutrition 21 Llc | Chromium containing compositions for improving health and fitness. |
MA43682A (en) * | 2016-02-26 | 2018-11-28 | Nogra Pharma Ltd | LACTOSE INTOLERANCE TREATMENT METHODS |
MX2021009498A (en) | 2019-02-08 | 2021-09-08 | Nogra Pharma Ltd | Process of making 3-(4'-aminophenyl)-2-methoxypropionic acid, and analogs and intermediates thereof. |
CN115245510A (en) * | 2021-04-28 | 2022-10-28 | 扬州大学 | Application of trans-10, cis-12 conjugated linoleic acid |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5948772A (en) * | 1998-08-28 | 1999-09-07 | Ambi Inc. | Chromium picolinate compositions and uses thereof |
-
2002
- 2002-11-12 WO PCT/US2002/036684 patent/WO2003043569A2/en not_active Application Discontinuation
- 2002-11-12 AU AU2002357729A patent/AU2002357729A1/en not_active Abandoned
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5948772A (en) * | 1998-08-28 | 1999-09-07 | Ambi Inc. | Chromium picolinate compositions and uses thereof |
US6093711A (en) * | 1998-08-28 | 2000-07-25 | Ambi Inc. | Enteric-coated chromium picolinate compositions and uses thereof |
Cited By (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9119835B2 (en) | 2007-03-13 | 2015-09-01 | JDS Therapeautics, LLC | Methods and compositions for the sustained release of chromium |
US9597404B2 (en) | 2007-03-13 | 2017-03-21 | Jds Therapeutics, Llc | Methods and compositions for sustained release of chromium |
US9005637B2 (en) | 2007-06-26 | 2015-04-14 | Jds Therapeutics, Llc | Multiple unit dosage form having a therapeutic agent in combination with a nutritional supplement |
US9421170B2 (en) | 2007-06-26 | 2016-08-23 | Jds Therapeutics, Llc | Multiple unit dosage form having a therapeutic agent in combination with a nutritional supplement |
US11850308B2 (en) | 2007-06-26 | 2023-12-26 | Bonafide Health, Llc | Multiple unit dosage form having a therapeutic agent in combination with a nutritional supplement |
US8933022B2 (en) | 2011-03-01 | 2015-01-13 | Jds Therapeutics, Llc | Methods and compositions for the treatment and prevention Hypoglycemia and related disorders |
Also Published As
Publication number | Publication date |
---|---|
AU2002357729A8 (en) | 2003-06-10 |
WO2003043569A2 (en) | 2003-05-30 |
AU2002357729A1 (en) | 2003-06-10 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2002024180A3 (en) | Chromium containing compositions for the treatment of diabetes, the reduction of body fat, improvement of insulin sensitivity and reduction of hyperglycemia and hypercholesteremia | |
WO1999062565A3 (en) | Patient-specific dosimetry | |
MXPA03006217A (en) | Spaced drug delivery system. | |
NO20003051L (en) | Method of administration of AspB28 human insulin | |
WO2002065985A3 (en) | Methods of treating diabetes mellitus | |
WO2006062748A3 (en) | Omega-3 fatty acids and dyslipidemic agent for lipid therapy | |
SG149814A1 (en) | Compositions and methods for treating diabetes | |
WO1995022965A3 (en) | Nasal and ocular administration of ketamine to manage pain and for detoxification | |
WO2005103687A3 (en) | System and method for providing optimal concentrations for medication infusions | |
WO2004050115A3 (en) | Combination treatment using exendin-4 and thiazolidinediones | |
WO2003043569A3 (en) | Trans-10, cis-12 conjugated linoleic acid isomer for the treatment of diseases | |
Sicard et al. | Local infiltration analgesia versus interscalene nerve block for postoperative pain control after shoulder arthroplasty: a prospective, randomized, comparative noninferiority study involving 99 patients | |
AU1569395A (en) | Method for treatment of obesity using prolactin modulators and diet | |
WO2005117937A3 (en) | Alpha-1- acid glycoprotein for the treatment of diabetes | |
WO2004032858A3 (en) | Method for cardioprotection and neuroprotection by intravenous administration of halogenated volatile anesthetics | |
AU1795101A (en) | Safety mechanism to prevent accidental patient injection and methods of same | |
LT2006024A (en) | Tetrapeptide regulating blood glucose level in diabetes mellitus | |
Lin | Acupuncture for persistent hiccups in a heart and lung transplant recipient | |
RU2002117537A (en) | A method for treating the effects of tissue hypoxia in critically ill patients | |
EP1752147A4 (en) | Drug for prevention or treatment of diabetes | |
CA3150837A1 (en) | Avocatin b for the treatment of diseases and conditions | |
Gonzalez et al. | Growth hormone replacement in patients with hypopituitarism and severe growth hormone deficiency | |
GB2603379A (en) | Avocatin B for the treatment of diseases and conditions | |
WO2009057461A1 (en) | Therapeutic agent for diabetes | |
Niafar et al. | Efficacy and Safety of Insulin Glargine in Type-2 Diabetes Mellitus Patients with Moderate Renal Failure |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SC SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
122 | Ep: pct application non-entry in european phase | ||
NENP | Non-entry into the national phase |
Ref country code: JP |
|
WWW | Wipo information: withdrawn in national office |
Country of ref document: JP |